Clinical trials: Retinitis Pigmentosa
Retinitis Pigmentosa (RP)
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP.
- Trial name
- NCT07311863
- Testing
- UGX202 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Suzhou UgeneX Therapeutics Co., Ltd.
Retinitis Pigmentosa, Cystoid Macular Edema
Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser
Purpose: To investigate the effects of subliminal micropulse yellow laser application on central macular thickness and best corrected visual acuity in cystoid macular edema secondary to retinitis pigmentosa patients.
- Trial name
- SL-MPL (NCT04234438)
- Testing
- SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Ankara Universitesi Teknokent
Retinitis Pigmentosa (RP)
Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa
This is a single-arm, open-label study employing a 3+3 dose escalation design to evaluate two UGX202 dose groups: the low-dose group (1.2×10¹¹ vg/eye) and the high-dose group (3.5×10¹¹ vg/eye).
- Trial name
- UGX202 (NCT07847723)
- Testing
- UGX202 Injection
- Volunteers
- 12 people
- Sponsor
- Suzhou UgeneX Therapeutics Co., Ltd.